-transparent.png){kind=logo}
Beta-adrenoceptor blockade is an effective treatment for ischemic heart disease and hypertension, but the more widespread use of beta antagonists is limited by their bronchoconstrictor, vasoconstrictor and negative inotropic properties. Celiprolol has been shown in preclinical studies to be a beta 1-selective antagonist with bronchosparing and vasodilating properties, but without any cardiodepressant effect. This has been confirmed by clinical studies undertaken to date. The aim of the present study was to examine the acute effects of intravenous celiprolol on the cardiac hemodynamics of patients pretreated with oral atenolol.
Related Publications
R M Donaldson, and
L A Williams, and
E H Lee
August 1991,
The American journal of cardiology,
R M Donaldson, and
L A Williams, and
E H Lee
July 1988,
American journal of hypertension,
R M Donaldson, and
L A Williams, and
E H Lee
January 1989,
Journal of cardiovascular pharmacology,
R M Donaldson, and
L A Williams, and
E H Lee
February 1988,
The American journal of cardiology,
R M Donaldson, and
L A Williams, and
E H Lee
January 1986,
Journal of cardiovascular pharmacology,
R M Donaldson, and
L A Williams, and
E H Lee
March 1999,
International journal of cardiology,
R M Donaldson, and
L A Williams, and
E H Lee
November 2001,
Journal of cardiovascular pharmacology,
R M Donaldson, and
L A Williams, and
E H Lee
July 1988,
Cardiovascular drugs and therapy,
R M Donaldson, and
L A Williams, and
E H Lee
March 2005,
Herzschrittmachertherapie & Elektrophysiologie,
R M Donaldson, and
L A Williams, and
E H Lee
April 1997,
Cardiovascular drugs and therapy,
